Cargando…
The natural history of COVID-19 in vaccinated inflammatory bowel disease patients
AIM: Assess the characteristics of break through COVID-19 in Inflammatory Bowel Disease (IBD) patients, despite complete vaccination. METHODS: Patients who reported a COVID-19 at least 3 weeks after complete vaccination were asked to answer an on-line anonymous questionnaire which included patient a...
Autores principales: | Viazis, N., Drygiannakis, I., Karmiris, K., Theodoropoulou, A., Zampeli, E., Tzouvala, M., Bamias, G., Liatsos, C., Theocharis, G., Vrakas, S., Tsironi, E., Mathou, N., Mantaka, A., Christidou, A., Koustenis, K., Veretanos, Ch., Papathanasiou, E., Zacharopoulou, E., Tribonias, G., Kitsou, V., Kartsoli, S., Theodoulou, A., Michopoulos, S., Thomopoulos, K., Koutroubakis, I.E., Mantzaris, G.J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843500/ https://www.ncbi.nlm.nih.gov/pubmed/36658043 http://dx.doi.org/10.1016/j.dld.2022.12.012 |
Ejemplares similares
-
Real-World Use and Adverse Events of SARS-CoV-2 Vaccination in Greek Patients with Inflammatory Bowel Disease
por: Orfanoudaki, Eleni, et al.
Publicado: (2022) -
Tu1550: REAL WORLD USE AND ADVERSE EVENTS OF SARS-COV-2 VACCINATION IN GREEK PATIENTS WITH INFLAMMATORY BOWEL DISEASE
por: Orfanoudaki, Eleni, et al.
Publicado: (2022) -
Tu1551: PATIENTS WITH INFLAMMATORY BOWEL DISEASES HAVE IMPAIRED ANTIBODY PRODUCTION AFTER ANTI-SARS-COV-2 VACCINATION, ESPECIALLY THOSE ON ANTI-TNFα OR COMBINATION TREATMENT OF BIOLOGICS PLUS IMMUNOMODULATORS: RESULTS FROM A PANHELLENIC REGISTRY
por: Zacharopoulou, Eirini, et al.
Publicado: (2022) -
The Inflammatory Bowel Disease—Disk Tool for Assessing Disability in Inflammatory Bowel Disease Patients: Validation of the Greek Version
por: Katsoula, Anastasia, et al.
Publicado: (2023) -
Clinical profiles of moderate and severe Crohn’s disease patients and use of anti-tumor necrosis factor agents: Greek expert consensus guidelines
por: Mantzaris, Gerassimos J., et al.
Publicado: (2015)